Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|January 5, 2022

BP Elements

  • BioPharm International's BP Elements, January 2022
  • Volume 1
  • Issue 1

OpenEye Scientific and Specifica Partner to Launch Orion Antibody Discovery Suite

The partnership between OpenEye Scientific and Specifica has generated AbXtract, an antibody discovery model that is included in the Orion Antibody Suite.

OpenEye Scientific and Specifa have jointly developed a software offering known as the OpenEye Orion Antibody Discovery Suite. The first offering from the suite will be AbXtract, an antibody discovery module developed by Specifica.

The Orion Antibody Suite has been described as the only cloud-native. fully integrated software-as-a-service molecular modeling platform, according to a Dec. 2, 2021, press release. The software suite is intended to combine the storage and computational scalability of Amazon Web Services with powerful tools for data sharing, visualization, and analysis in an open development platform.

AbXtract uses proprietary artificial intelligence methods to analyze large amounts of sequence data. The model is designed to help antibody engineers and bioinformaticians uncover diverse antibody sets with ideal properties for downstream therapeutics development.

“What AbXtract does is democratize the use of next-generation sequencing in antibody discovery, letting Orion take care of storage and analysis,” said Andrew Bradbury, co-founder and chief scientific officer of Specifica, in the press release. “Antibody discovery projects that were previously out of reach because of software, hardware, computation, or data sharing limitations have now become possible with AbXtract on Orion.”

Source: Specifica

Articles in this issue

almost 5 years ago

Elements that are Key for Successful Assay Transfer

almost 5 years ago

COVID Pandemic Prompts Renewed Interest in Biotech Startups

almost 5 years ago

Bio-Rad Introduces SARS-CoV-2 Variant Neutralization Antibody Assays

almost 5 years ago

FDA Accepts IND for Poseida Therapeutics’ Allogeneic CAR-T Cell Therapy Candidate

almost 5 years ago

Insightful Science Completes Acquisition of Protein Metrics

almost 5 years ago

New High Fidelity CRISPR Cas9 Protein Reduces Off-Target Effects

almost 5 years ago

Amgen Extends Collaboration with Syngene International

almost 5 years ago

Genezen Starts Up Operations at Lenti- and Retroviral Vector Process Development Lab

almost 5 years ago

GSK and University of Oxford Partner on Disease Research to Advance Drug Discovery and Development

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more